Fennec Pharmaceuticals Announces InvestigatorSponsored Study to Be Conducted by University of Arizona Cancer Center
News Source : Financial Post
News Summary
- University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin.
- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX) recently announced the initiation of two other institution-led clinical studies.
- Additional investigator-initiated studies supporting the use of PedMark® have been submitted to Fennec and are currently under review.
- PEDmARK is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors.
- It is also recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in adolescent and young adult patients.
Important Safety Information PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.Hypersensitivity reactions occurred in 8 [+5274 chars]
Never miss a story from us, subscribe to our newsletter